Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.
Mutations of parkin, a protein-ubiquitin E3 ligase, are linked to Parkinson's disease (PD). Although a variety of parkin substrates have been identified, none of these is selectively expressed in dopaminergic neurons, whose degeneration plays a critical role in PD. Here we show that parkin significantly increased dopamine uptake in the human dopaminergic neuroblastoma cell line SH-SY5Y. This effect was accompanied by increased V(max) of dopamine uptake and unchanged K(m). Consistent with this, increased binding sites for dopamine transporter (DAT) ligand were observed in SH-SY5Y cells overexpressing parkin. The results were confirmed when parkin was transfected in HEK293 cells stably expressing DAT. In these cells, parkin enhanced the ubiquitination and degradation of DAT, increased its cell surface expression, and augmented dopamine uptake. The effects of parkin were significantly abrogated by its PD-causing mutations. Because the cell surface expression of functional DAT requires its oligomerization, misfolded DAT, induced either by the protein glycosylation inhibitor tunicamycin or by its C-terminal truncation, significantly attenuated cell surface expression of native DAT and reduced dopamine uptake. Expression of parkin, but not its T240R mutant, significantly alleviated these detrimental effects of misfolded DAT. Thus, our studies suggest that parkin increases dopamine uptake by enhancing the ubiquitination and degradation of misfolded DAT, so as to prevent it from interfering with the oligomerization and cell surface expression of native DAT. This function of parkin would enhance the precision of dopaminergic transmission, increase the efficiency of dopamine utilization, and reduce dopamine toxicity on neighboring cells.
Jiang
Houbo
H
Department of Physiology and Biophysics, State University of New York at Buffalo, Buffalo, New York 14214, USA.
Jiang
Qian
Q
Feng
Jian
J
D000818:Animals; D002460:Cell Line; D003001:Cloning, Molecular; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins; D015870:Gene Expression; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000235:genetics* / Q000502:physiology; D026901:Membrane Transport Proteins / Q000737:chemistry / Q000235:genetics* / Q000502:physiology; D051379:Mice; D016296:Mutagenesis; D009419:Nerve Tissue Proteins / Q000737:chemistry / Q000235:genetics* / Q000502:physiology; D009447:Neuroblastoma; D016133:Polymerase Chain Reaction; D017510:Protein Folding; D013329:Structure-Activity Relationship; D014162:Transfection; D014316:Tritium; D014407:Tumor Cells, Cultured; D014415:Tunicamycin; D025801:Ubiquitin / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000502:physiology*
D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493214:SLC6A3 protein, human; C493215:Slc6a3 protein, mouse; D025801:Ubiquitin; D014316:Tritium; D014415:Tunicamycin; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein; D004298:Dopamine